1792 Exchange Urges Major Pharmacies to Protect Women from the Harms of the Abortion Pill
Media Contact: [email protected]
SPRINGBORO, OH — 1792 Exchange is calling on senior executives and board members at leading U.S. pharmacies to take immediate action in response to new research highlighting serious health risks linked to the abortion drug mifepristone.
In a letter to the leadership of CVS, Walgreens, and Rite Aid, 1792 Exchange provides the alarming safety data found in a comprehensive study released by the Ethics and Public Policy Center (EPPC).
“At a minimum, every pharmacy chain should be concerned about dispensing drugs that are harmful to women,” said Daniel Cameron, 1792 Exchange CEO. “With this new data covered in the EPPC paper, continued reliance on outdated or inaccurate information from the manufacturer is both unreasonable and risky. Ignoring this data could expose pharmacies and their pharmacists to legal and financial liability. The most prudent course of action is to suspend dispensing this so-called medication until the FDA conducts a thorough review.”
The EPPC study— the most extensive real-world analysis of mifepristone to date—found that 10.93% of women experienced serious adverse events, including sepsis, hemorrhage, infection, or surgery, within 45 days of use. This rate is more than 22 times higher than the “less than 0.5%” adverse event rate currently listed on the FDA-approved label.
Given that pharmacies now possess credible data indicating a 1-in-10 risk of serious complications, failure to inform patients or their physicians may violate common law and statutory duties. Pharmacists have a well-established responsibility to counsel patients when aware of significant risks.
1792 Exchange also noted growing concern about the profit motives surrounding mifepristone’s distribution. Since the FDA’s 2023 decision to lift in-person dispensing requirements, the drug’s market share has expanded rapidly. Parallels are being drawn to the opioid crisis, where aggressive marketing and under-communicated risks led to major legal consequences for pharmaceutical stakeholders.
To help these companies mitigate both reputational risk and legal exposure, 1792 Exchange has provided pharmacy leaders with guidance on practical steps to safeguard patients and align practices with evolving safety data.
Read the letter here and the EPPC paper here.
###
1792 Exchange is a 501(c)(3), educational, non-profit organization whose mission is to preserve freedom by steering public companies back to neutral on ideological issues. We create Spotlight Bias Reports, policies, and resources that expose coercion and corporate bias. We protect First Amendment freedoms and ensure all viewpoints have a seat at the table. We help corporate board members and executives maximize shareholder value, respect stakeholders, return to cultural neutrality, and serve customers with excellence and integrity. We also educate Congress, other leaders, and the American people about the dangers of stakeholder capitalism to safeguard Free Exercise, Free Speech, and Free Enterprise.